Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Veliparib in Recurrent BRCA-Mutated Ovarian Cancer
NCT01540565Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Apr 2012
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of veliparib in ovarian epithelial cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by National Cancer Institute. Started Apr 2012; status: completed.
02
Drugs
veliparib
03
Conditions
ovarian epithelial cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT01540565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01540565.